Among breast cancer patients with germline BRCA1/2 mutations, the PARP inhibitors olaparib and talazoparib have demonstrated clinical efficacy in the metastatic setting, as confirmed by the OlympiAD and EMBRACA trials, respectively [74,75,76,77]. This evidence concerns the gene BRCA1 and breast carcinoma.